No recommendation
No news or research item is a personal recommendation to deal. Hargreaves Lansdown may not share ShareCast's (powered by Digital Look) views.
(Sharecast News) - France's Sanofi said on Wednesday that it has agreed to buy US hepatitis vaccine maker Dynavax in a $2.2bn deal.
Dynavax's adult hepatitis B vaccine is currently marketed in the US, while its shingles vaccine candidate is in phase 1/2 clinical development.
The company said the acquisition augments its presence in adult immunisation by bringing together Dynavax's vaccines with Sanofi's "global scale, development capabilities and commercial reach".
Under the terms of the deal, Sanofi will start a cash tender offer to buy all outstanding shares of Dynavax for $15.50 per share.
Thomas Triomphe, executive vice president of vaccines at Sanofi, said: "Dynavax enhances Sanofi's adult immunisation presence by adding differentiated vaccines that complement Sanofi's expertise.
"Its marketed adult hepatitis B vaccine and shingles candidate bring new options to our portfolio and underscore our commitment to providing vaccine protection across the lifespan."
The acquisition, which is due to close in the first quarter of next year, is not expected to have any impact on Sanofi's financial guidance for 2025.
The value of investments can go down in value as well as up, so you could get back less than you invest. It is therefore important that you understand the risks and commitments. This website is not personal advice based on your circumstances. So you can make informed decisions for yourself we aim to provide you with the best information, best service and best prices. If you are unsure about the suitability of an investment please contact us for advice.